Radiation myelopathy: New perspective on an old problem

Radiation Oncology Investigations

Volumn 7, Issue 4, 1999, Pages 193-203

  Nieder, Carsten ^a   Ataman, Fatma ^a   Price, Roger E ^b   Ang, K Kian ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Cytokines; Oligodendroglia; Radiation myelopathy; Radiation therapy; Spinal cord

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR;

HUMAN; OLIGODENDROGLIA; PATHOGENESIS; PRIORITY JOURNAL; RADIATION HAZARD; RADIATION INJURY; REVIEW; SPINAL CORD DISEASE;

ANIMALS; CELL DIFFERENTIATION; CYTOKINES; DEMYELINATING DISEASES; HUMANS; MYELIN SHEATH; RADIATION INJURIES; RADIOTHERAPY; SPINAL CORD; SPINAL CORD DISEASES;

EID: 0032886846     PISSN: 10657541     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-6823(1999)7:4<193::AID-ROI1>3.0.CO;2-S     Document Type: Review

References (81)

1. van der Kogel AJ. Radiation response and tolerance of normal tissues. In: Steel GG, editor. Basic clinical radiobiology, 2nd ed. London: Arnold; 1997. p 30-39.
2. Schultheiss TE, Kun LE, Ang KK, Stephens LC. Radiation response of the central nervous system. Int J Radiat Oncol Biol Phys 1995;31:1093-1112.
3. Raff MC, Miller RH, Noble M. A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on the culture medium. Nature 1983; 303:390-396.
4. van der Kogel AJ. The cellular basis of radiation-induced damage in the central nervous system. In: Potten CS, Hendry JH, editors. Cytotoxic insult to tissue. Edinburgh, London, New York: Churchill Livingstone; 1983. p 329-352.
5. Stewart FA. Re-treatment tolerance of normal tissues. In: Steel GG, editor. Basic clinical radiobiology, 2nd ed. London: Arnold; 1997. p 203-211.
6. Stewart FA, van der Kogel AJ. Proliferation and cellular organisation of normal tissues. In: Steel GG, editor. Basic clinical radiobiology, 2nd ed. London: Arnold; 1997. p 24-29.
7. Herskind C, Bamberg M, Rodemann HP. The role of cytokines in the development of normal-tissue reactions after radiotherapy. Strahlenther Oncol 1998;174(Suppl. III):12-15.
8. McKay R. Stem cells in the central nervous system. Science 1997;276:66-71.
9. Wolswijk G, Noble M. Identification of an adult-specific glial progenitor cell. Development 1989;105: 387-400.
10. Wren D, Wolswijk G, Noble M. In vitro analysis of origin and maintenance of O-2A adult progenitor cells. J Cell Biol 1992;116:167-176.
11. Vos JP, Gard AL, Pfeiffer SE. Regulation of oligodendrocyte cell survival and differentiation by ciliary neurotrophic factor, leukemia inhibitory factor, oncostatin M, and interleukin-6. Perspect Dev Neurobiol 1996;4: 39-52.
12. Grinspan JB, Stern JL, Pustilnik SM, Pleasure D. Cerebral white matter contains PDGF-responsive precursors to O-2A cells. J Neurosci 1990;10:1861-1873.
13. Levine JM, Stincone F, Lee YS. Development and differentiation of glial precursor cells in the rat cerebellum. Glia 1993;7:307-321.
14. Wolswijk G, Riddle PN, Noble M. Platelet-derived growth factor is mitogenic for O-2A adult progenitor cells. Glia 1991;4:495-503.
15. Engel U, Wolswijk G. Oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells derived from adult rat spinal cord: in vitro characteristics and response to PDGF, bFGF and NT-3. Glia 1996;16:16-26.
16. Hunter SF, Leavitt JA, Rodriguez M. Direct observation of myelination in vivo in the mature human central nervous system. A model for the behaviour of oligodendrocyte progenitors and their progeny. Brain 1997; 120:2071-2082.
17. van der Maazen RW, Kleiboer BJ, Verhagen I, van der Kogel AJ. Repair capacity of adult rat glial progenitor cells determined by an in vitro clonogenic assay after in vitro or in vivo fractionated irradiation. Int J Radiat Biol 1993;63:661-666.
18. Kahn MA, de Velus J. Growth factors in the CNS and their effects on oligodendroglia. Prog Brain Res 1995; 105:145-169.
19. Calver AR, Hall AC, Yu WP, Walsh FS, Heath JK, Betsholtz C, Richardson WD. Oligodendrocyte population dynamics and the role of PDGF in vivo. Neuron 1998;20:869-882.
20. Noble M, Murray K, Stroobant P, Waterfield MD, Riddle P. Platelet-derived growth factor promotes division and motility and inhibits premature differentiation of the oligodendrocyte/type-2 astrocyte progenitor cell. Nature 1988;333:560-562.
21. Raff MC, Lillien LE, Richardson WD, Burne JF, Noble M. Platelet-derived growth factor from astrocytes drives the clock that times oligodendrocyte development in culture. Nature 1988;333:562-565.
22. Pringle N, Collarini EJ, Mosley MJ, Heldin CH, Westermark B, Richardson WD. PDGF-A chain homodimers drive proliferation of bipotential (O-2A) glial progenitor cells in the developing rat optic nerve. EMBO J 1989;8:1049-1056.
23. McKinnon RD, Matsui T, Dubois-Dalcq M, Aaronson SA. FGF modulates the PDGF-driven pathway of oligodendrocyte development. Neuron 1990;5:603-614.
24. Nathan C, Sporn M. Cytokines in context. J Cell Biol 1991;113:981-986.
25. Mayer M, Boegler O, Noble M. The inhibition of oligodendrocytic differentiation of O-2A progenitors caused by basic fibroblast growth factor is overriden by astrocytes. Glia 1993;8:12-19.
26. McMorris FA, McKinnon RD. Regulation of oligodendrocyte development and CNS myelination by growth factors: prospects for therapy of demyelinating disease. Brain Pathol 1996;6:313-329.
27. Gard AL, Pfeiffer SE. Glial cell mitogens bFGF and PDGF differentially regulate development of O4+ GalC- oligodendrocyte progenitors. Dev Biol 1993; 159:618-630.
28. Wolswijk G, Noble M. Cooperation between PDGF and FGF converts slowly dividing O-2A adult progenitor cells to rapidly dividing cells with characteristics of O-2A perinatal progenitor cells. J Cell Biol 1992;118: 889-900.
29. Cohen RI, Marmur R, Norton WT, Mehler MF, Kessler JA. Nerve growth factor and neurotrophin-3 differentially regulate the proliferation and survival of developing rat brain oligodendrocytes. J Neurosci 1996;16: 6433-6442.
30. Milner R, Anderson HJ, Rippon RF, McKay JS, Franklin RJ, Marchionni MA, Reynolds R, Ffrench-Constant C. Contrasting effects of mitogenic growth factors on oligodendrocyte precursor cell migration. Glia 1997; 19:85-90.
31. McKinnon RD, Piras G, Ida JA, Dubois-Dalcq M. A role for TGF-β in oligodendrocyte differentiation. J Cell Biol 1993;121:1397-1407.
32. Mayer M, Bhakoo K, Noble M. Ciliary neurotrophic factor and leukemia inhibitory factor promote the generation, maturation and survival of oligodendrocytes in vitro. Development 1994;120:143-153.
33. Pfeiffer SE, Warrington AE, Bansal R. The oligodendrocyte and its many cellular processes. Trends Cell Biol 1993;3:191-197.
34. Grinspan JB, Reeves MF, Coulaloglou MJ, Nathanson D, Pleasure D. Re-entry into the cell cycle is required for bFGF-induced oligodendroglial dedifferentiation and survival. J Neurosci Res 1996;46:456-464.
35. Barres BA, Hart IK, Coles HS, Burne JF, Voyvodic JT, Richardson WD, Raff MC. Cell death and control of cell survival in the oligodendrocyte lineage. Cell 1992; 70:31-46.
36. Bansal R, Pfeiffer SE. FGF-2 converts mature oligodendrocytes to a novel phenotype. J Neurosci Res 1997; 50:215-228.
37. Harari D, Finkelstein D, Bernard O. FGF plays a subtle role in oligodendrocyte maintenance in vivo. J Neurosci Res 1997;49:404-415.
38. Barres BA, Schmid R, Sendtner M, Raff MC. Multiple extracellular signals are required for long-term oligodendrocyte survival. Development 1993;118:283-295.
39. Liu X, Yao DL, Webster HD. Insulin-like growth factor-1 treatment reduces clinical deficits and lesion severity in acute demyelinating experimental autoimmune encephalomyelitis. Mult Scler 1996;1:2-9.
40. Yao DL, Liu X, Hudson LD, Webster HD. Insulin-like growth factor-1 treatment reduces demyelination and up-regulates gene expression of myelin-related proteins in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 1995;92:6190-6194.
41. Hatton R, Rapp RP, Kudsk KA, Brown RO, Dempsey RJ, Young B. Intravenous IGF-I in moderate-to-severe head injury: a phase II trial. J Neurosurg 1997;86:779-786.
42. Bondy CA, Underwood CE, Clemmons DR, Guler HP, Bach MA, Skarulis M. Clinical uses of insulin-like growth factor-1. Ann Intern Med 1994;120:593-601.
43. Grinspan JB, Stern JL, Franceschini B, Pleasure D. Trophic effects of basic fibroblast growth factor on differentiated oligodendroglia: a mechanism for regeneration of the oligodendroglial lineage. J Neurosci Res 1993; 36:672-680.
44. Wood PM, Bunge RP. The origin of remyelinating cells in the adult central nervous system: the role of the mature oligodendrocyte. Glia 1991;4:225-232.
45. Li YQ, Jay V, Wong CS. Oligodendrocytes in the adult rat spinal cord undergo radiation-induced apoptosis. Cancer Res 1996;56:5417-5422.
46. McMorris FA, Mozell RL, Carson MJ, Shinar Y, Meyer RD, Marchetti N. Regulation of oligodendrocyte development and central nervous system myelination by insulin-like growth factors. Ann NY Acad Sci 1993;692: 321-334.
47. Carson M, Behringer RR, Brinster RL, McMorris FA. Insulin-like growth factor-1 increases brain growth and central nervous system myelination in transgenic mice. Neuron 1993;10:729-740.
48. Webster HD. Growth factors and myelin regeneration in multiple sclerosis. Mult Scler 1997;3:113-120.
49. Fine HA, Pluard T. Tumor angiogenesis: biology and therapeutic implications. In: Mauch P, Loeffler JS, editors. Radiation oncology - technology and biology. Philadelphia: Saunders; 1994. p 487-507.
50. Fu X, Shen Z, Cnen Y, Xie J, Guo Z, Zhang M, Sheng Z. Randomized placebo-controlled trial of use of topical recombinant bovine bFGF for second-degree burns. Lancet 1998;352:1661-1664.
51. Fuks Z, Persaud RS, Alfieri A, Cordon-Cardo C. Basic fibroblast growth factor protects endothelial cells from radiation-induced programmed cell death in vitro and in vivo. Cancer Res 1994;54:2582-2590.
52. Fuks Z, Alfieri A, Haimovitz-Friedman A, Seddon A, Cordon-Cardo C. Intravenous bFGF protects the lung but not mediastinal organs against radiation-induced apoptosis in vivo. Cancer J Sci Am 1995;1:62-72.
53. Tee PG, Travis EL. Basic fibroblast growth factor does not protect against classical radiation pneumonitis in two strains of mice. Cancer Res 1995;55:298-302.
54. Pimentel E. Handbook of growth factors, vol. III. Boca Raton, FL, Ann Arbor, MI: CRC Press; 1994. p 293-334.
55. Pimentel E. Handbook of growth factors, vol. II. Boca Raton, FL, Ann Arbor, MI: CRC Press; 1994. p 55-96.
56. Howarth GS, Fraser R, Frisby CL, Schirmer MB, Yeoh EK. Effects of insulin-like growth factor-I administration on radiation enteritis in rats. Scand J Gastroenterol 1997;32:1118-1124.
57. Fouque D. Growth factors: future prospects in renal failure. Miner Electrolyte Metab 1998;24:27-33.
58. Boonen S, Broos P, Dequeker J, Bouillon R. The prevention or treatment of age-related osteoporosis in the elderly by systemic recombinant growth factor therapy: a perspective. J Intern Med 1997;242:285-290.
59. Hallahan DE, Virudachalam S, Sherman ML, Huberman E, Kufe DW, Weichselbaum RR. Tumor necrosis factor gene expression is mediated by protein kinase C after activation by ionizing radiation. Cancer Res 1991; 51:4565-4569.
60. Merrill JE. Effects of interleukin-1 and tumor necrosis factor-α on astrocytes, microglia, oligodendrocytes and gual precursors in vitro. Dev Neurosci 1991;13:130-137.
61. Slungaard A, Vercellotti GM, Walker G, Nelson RD, Jacobs HS. Tumor necrosis factor-α/cachectin stimulates eosinophil oxidant production and toxicity towards human endothelium. J Exp Med 1990;171:2025-2041.
62. Baron W, de Jonge JC, de Vries H, Hoekstra D. Regulation of oligodendrocyte differentiation: protein kinase C activation prevents differentiation of O-2A progenitor cells toward oligodendrocytes. Glia 1998;22:121-129.
63. Louis JC, Magal E, Takayama S, Varon S. CNTF protection of oligodendrocytes against natural and tumor necrosis factor induced death. Science 1993;259:689-692.
64. Noble M, Mayer-Proschel M. On the track of cell survival pharmaceuticals in the oligodendrocyte type-2 astrocyte lineage. Perspect Dev Neurobiol 1996;3:121-131.
65. Melchiorri D, Reiter RJ, Sewerynek E, Chen LD, Nistico G. Melatonin reduces kainate-induced lipid peroxidation in homogenates of different brain regions. FASEB J 1995;9:1205-1208.
66. Ang KK, van der Kogel AJ, van der Schueren E. Lack of evidence of increased tolerance of rat spinal cord with decreasing fraction doses below 2 Gy. Int J Radiat Oncol Biol Phys 1985;11:105-111.
67. van der Schueren E, Landuyt W, Ang KK. From 2 Gy to 1 Gy per fraction: sparing effect in rat spinal cord? Int J Radiat Oncol Biol Phys 1988;14:297-300.
68. Ang KK, Jiang GL, Guttenberger R, Thames HD, Stephens LC, Smith CD, Feng Y. Impact of spinal cord repair kinetics on the practice of altered fractionation schedules. Radiother Oncol 1992;25:287-294.
69. Landuyt W, Fowler J, Ruifrok A, Stueben G, van der Kogel AJ, van der Schueren E. Kinetics of repair in the spinal cord of the rat. Radiother Oncol 1997;45:55-62.
70. Niewald M, Feldmann U, Feiden W, Niedermayer I, Kiessling M, Lehmann W, Abel U, Berberich W, Staut W, Buscher E, Walter K, Nieder C, Nestle U, Deinzer M, Schnabel K. Multivariate logistic analysis of dose-effect relationship and latency of radiomyelopathy after hyperfractionated and conventionally fractionated radiotherapy in animal experiments. Int J Radiat Oncol Biol Phys 1998;41:681-688.
71. Hopewell JW, van den Aardweg GJ, Morris GM, Rezvani M, Robbins ME, Ross GA, Whitehouse EM. Unsaturated lipids as modulators of radiation damage in normal tissues. In: Horrobin DF, editor. New approaches to cancer treatment. London: Churchill Communications Europe; 1994. p 88-106.
72. El-Agamawi AY, Hopewell JW, Plowman PN, Rezvani M, Wilding D. Modulation of normal tissue responses to radiation. Br J Radiol 1996;69:374-375.
73. Hornsey S, Myers R, Jenkinson T. The reduction of radiation damage to the spinal cord by post-irradiation administration of vasoactive drugs. Int J Radiat Oncol Biol Phys 1990;18:1437-1442.
74. Spence AM, Krohn KA, Edmondson SW, Steele JE, Rasey JS. Radioprotection in rat spinal cord with WR-2721 following cerebral lateral intraventricular injection. Int J Radiat Oncol Biol Phys 1986;12:1479-1482.
75. Fike JR, Gobbel GT, Marton LJ, Seilhan TM. Radiation brain injury is reduced by the polyamine inhibitor α-difluoromethylornithine. Radiat Res 1994;138:99-106.
76. Duncan ID, Paino C, Archer DR, Wood PM. Functional capacities of transplanted cell-sorted adult oligodendrocytes. Dev Neurosci 1992;14:114-122.
77. Franklin RJ, Blakemore WF. Transplanting oligodendrocyte progenitors into the adult CNS. J Anat 1997; 190:23-33.
78. Groves AK, Barnett SC, Franklin RJ, Crang AJ, Mayer M, Blakemore WF, Noble M. Repair of demyelinated lesions by transplantation of purified O-2A progenitor cells. Nature 1993;362:453-455.
79. Franklin RJ, Bayley SA, Milner R, Ffrench-Constant C, Blakemore WJ. Differentiation of the O-2A progenitor cell line CG-4 into oligodendrocytes and astrocytes following transplantation into glia-deficient areas of CNS white matter. Glia 1995;13:39-44.
80. Trotti A. Toxicity antagonists in head and neck cancer. Sem Rad Oncol 1998;8:282-291.
81. Ijichi A, Noel F, Sakuma S, Weil MM, Tofilon PJ. Ex vivo gene delivery of platelet-derived growth factor increases O-2A progenitors in adult rat spinal cord. Gene Ther 1996;3:389-395.